Fig. 1From: Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitorsST-ICI trial: irAE assessment. Assessment of irAE with easily routinely usable binary response questions (yes/no) focusing on the most affected organ systemsBack to article page